154 related articles for article (PubMed ID: 36740185)
1. Protein Kinase D2 and D3 Promote Prostate Cancer Cell Bone Metastasis by Positively Regulating Runx2 in a MEK/ERK1/2-Dependent Manner.
Roy A; Prasad S; Chen Y; Chao Y; Liu Y; Zhao J; Wang QJ
Am J Pathol; 2023 May; 193(5):624-637. PubMed ID: 36740185
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of protein kinase D suppresses epithelial ovarian cancer via MAPK/ERK1/2/Runx2 signalling axis.
Tyagi K; Roy A; Mandal S
Cell Signal; 2023 Oct; 110():110849. PubMed ID: 37562720
[TBL] [Abstract][Full Text] [Related]
3. PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA.
Zou Z; Zeng F; Xu W; Wang C; Ke Z; Wang QJ; Deng F
J Cell Sci; 2012 Oct; 125(Pt 20):4800-11. PubMed ID: 22797919
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment.
Xu W; Qian J; Zeng F; Li S; Guo W; Chen L; Li G; Zhang Z; Wang QJ; Deng F
J Exp Clin Cancer Res; 2019 Mar; 38(1):114. PubMed ID: 30841931
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2.
Chen J; Deng F; Singh SV; Wang QJ
Cancer Res; 2008 May; 68(10):3844-53. PubMed ID: 18483269
[TBL] [Abstract][Full Text] [Related]
6. A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-{kappa}B activities.
Chen J; Giridhar KV; Zhang L; Xu S; Wang QJ
Carcinogenesis; 2011 Aug; 32(8):1198-206. PubMed ID: 21665893
[TBL] [Abstract][Full Text] [Related]
7. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
[TBL] [Abstract][Full Text] [Related]
8. Protein Kinase D3 (PKD3) Requires Hsp90 for Stability and Promotion of Prostate Cancer Cell Migration.
Varga A; Nguyen MT; Pénzes K; Bátai B; Gyulavári P; Gurbi B; Murányi J; Csermely P; Csala M; Vántus T; Sőti C
Cells; 2023 Jan; 12(2):. PubMed ID: 36672148
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase D activity is a risk biomarker in prostate cancer that drives cell invasion by a Snail/ERK dependent mechanism.
Cilleros-Rodríguez D; Toledo-Lobo MV; Martínez-Martínez D; Baquero P; Angulo JC; Chiloeches A; Iglesias T; Lasa M
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166851. PubMed ID: 37611675
[TBL] [Abstract][Full Text] [Related]
10. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion.
Zhang H; Pan Y; Zheng L; Choe C; Lindgren B; Jensen ED; Westendorf JJ; Cheng L; Huang H
Cancer Res; 2011 May; 71(9):3257-67. PubMed ID: 21505104
[TBL] [Abstract][Full Text] [Related]
11. Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells.
Hao Q; McKenzie R; Gan H; Tang H
Anticancer Res; 2013 Feb; 33(2):393-9. PubMed ID: 23393329
[TBL] [Abstract][Full Text] [Related]
12. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.
Dey P; Jonsson P; Hartman J; Williams C; Ström A; Gustafsson JÅ
Mol Endocrinol; 2012 Dec; 26(12):1991-2003. PubMed ID: 23028063
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase d as a potential chemotherapeutic target for colorectal cancer.
Wei N; Chu E; Wipf P; Schmitz JC
Mol Cancer Ther; 2014 May; 13(5):1130-41. PubMed ID: 24634417
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.
Colden M; Dar AA; Saini S; Dahiya PV; Shahryari V; Yamamura S; Tanaka Y; Stein G; Dahiya R; Majid S
Cell Death Dis; 2017 Jan; 8(1):e2572. PubMed ID: 28125091
[TBL] [Abstract][Full Text] [Related]
16. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.
Harikumar KB; Kunnumakkara AB; Ochi N; Tong Z; Deorukhkar A; Sung B; Kelland L; Jamieson S; Sutherland R; Raynham T; Charles M; Bagherzadeh A; Foxton C; Boakes A; Farooq M; Maru D; Diagaradjane P; Matsuo Y; Sinnett-Smith J; Gelovani J; Krishnan S; Aggarwal BB; Rozengurt E; Ireson CR; Guha S
Mol Cancer Ther; 2010 May; 9(5):1136-46. PubMed ID: 20442301
[TBL] [Abstract][Full Text] [Related]
17. Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.
Tandon M; Chen Z; Othman AH; Pratap J
Oncogene; 2016 Sep; 35(36):4730-40. PubMed ID: 26804175
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic functions of protein kinase D2 and D3 in regulating multiple cancer-related pathways in breast cancer.
Liu Y; Li J; Ma Z; Zhang J; Wang Y; Yu Z; Lin X; Xu Z; Su Q; An L; Zhou Y; Ma X; Yang Y; Wang F; Chen Q; Zhang Y; Wang J; Zheng H; Shi A; Yu S; Zhang J; Zhao W; Chen L
Cancer Med; 2019 Feb; 8(2):729-741. PubMed ID: 30652415
[TBL] [Abstract][Full Text] [Related]
19. TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction.
Yuen HF; Kwok WK; Chan KK; Chua CW; Chan YP; Chu YY; Wong YC; Wang X; Chan KW
Carcinogenesis; 2008 Aug; 29(8):1509-18. PubMed ID: 18453541
[TBL] [Abstract][Full Text] [Related]
20. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease.
Ge C; Zhao G; Li Y; Li H; Zhao X; Pannone G; Bufo P; Santoro A; Sanguedolce F; Tortorella S; Mattoni M; Papagerakis S; Keller ET; Franceschi RT
Oncogene; 2016 Jan; 35(3):366-76. PubMed ID: 25867060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
